PAX-101 (IV Suramin) for ASD
PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting anti-purinergic therapy and has reported positive results from a dose range study. The results of our Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
![ASD Kid at the hospital](https://cdn.prod.website-files.com/6352918928ba360c7d5ba8e0/63776cbac7a7e9f583d15df8_asd.webp)
![Nose](https://cdn.prod.website-files.com/6352918928ba360c7d5ba8e0/63778197964b877277847492_aerosol-nasal.webp)
PAX-102 (Intranasal Suramin)
PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
![Mitocondria](https://cdn.prod.website-files.com/6352918928ba360c7d5ba8e0/637781972e01c5e4a45c56e2_mitocondria.webp)
Selective APTs
PaxMedica has conducted several preclinical studies to evaluate other anti-purinergic therapies (APTs) that are more selective to specific purinergic receptors and may offer additional benefits over suramin.